DMT models the near-death experience

Near-death experiences (NDEs) are complex subjective episodes that occur in association with death or the perception that death is imminent. Common phenomenological features reported in NDEs include intense feelings of peace, out-of-body experiences, travelling through a void or tunnel toward a bright light, entering an otherworldly realm, and encounters or communications with sentient beings. The authors note longstanding qualitative similarities between NDE reports and the effects of the serotonergic psychedelic N,N-dimethyltryptamine (DMT), including feelings of transcending the body, encounters with presences or entities, vividness described as 'realer than real', and themes relating to death and dying. Previous suggestions that endogenous DMT might be released during the dying process have been influential but contested, and systematic, instrumented comparisons between drug-induced states and bona fide NDEs have not been performed using a standard NDE instrument. Timmermann and colleagues set out to test directly whether intravenous DMT administered to healthy volunteers in a laboratory setting can induce experiences that resemble NDEs as measured by a validated Near-Death Experience (NDE) scale. The study also aimed to compare DMT-induced NDE scores with those from a gender- and age-matched sample of individuals reporting actual NDEs, and to examine whether baseline traits such as absorption, delusional ideation and age predict the magnitude of DMT-induced NDE-like phenomena. The principal hypothesis was that DMT would produce NDE-type experiences of comparable intensity to actual NDEs and significantly greater than placebo, and that personality and belief measures would be associated with those experiences.

This was a within-subjects, placebo-controlled, single-blind study involving 13 healthy volunteers (6 female, 7 male; mean age 34.4, SD 9.1). Screening included medical tests, ECG, psychiatric interview and urine/pregnancy drug screens. Key exclusion criteria were lack of prior classic psychedelic experience, current or past psychiatric illness, immediate family history of psychotic disorder, excessive alcohol use, severe medical conditions, and phobia of blood/needles. Participants abstained from psychoactive drugs for at least 7 days prior to sessions. Each participant completed two dosing sessions in a clinical research facility. Placebo (2 ml sterile saline) was always administered in the first session and intravenous DMT fumarate in the second session one week later, making the study single-blind (participants unaware, research team aware). DMT was delivered intravenously as a 2 ml sterile solution over 30 s followed by a 5 ml saline flush; doses varied across volunteers (three received 7 mg, four 14 mg, one 18 mg and five 20 mg) because this was part of a dose-finding pre-study. Participants rested reclined in a dim room with low-volume music; EEG was recorded before and after dosing (EEG results reported elsewhere). Subjective effects peaked at about 2–3 minutes and largely resolved by 20 minutes. The primary outcome was the Greyson NDE scale, a 16-item instrument yielding a total score and four subscale scores (Cognitive, Affective, Transcendental, Paranormal); a total score ≥7 is conventionally taken as the threshold for an NDE. Secondary or complementary measures included the Ego Dissolution Inventory (EDI; eight items, single factor) and the Mystical Experience Questionnaire (MEQ; 30 items yielding a total and four subscales: Mystical, Positive Mood, Transcendence of Time and Space, Ineffability). Baseline questionnaires included the modified Tellegen Absorption Scale (MODTAS) and the Peters' Delusion Inventory (PDI) to probe relationships between absorption, delusional ideation and NDE scores. A separate gender- and age-matched comparison group (n = 13; mean time since event ~7 years) of individuals who had experienced bona fide NDEs and scored ≥7 on the NDE scale was assembled for between-group comparison. Statistical procedures involved repeated-measures ANOVA on NDE and MEQ data with condition (DMT vs. placebo) and subscales as factors, followed by post hoc paired t-tests. Each NDE item was also compared via paired t-tests. Correlations between the DMT–placebo difference scores on NDE, EDI and MEQ were assessed with Pearson product-moment correlations; independent correlations between NDE difference scores and MEQ subfactors were performed to identify the strongest associations. Correlations between baseline traits (MODTAS, PDI, age) and NDE scores used Pearson correlations; one-tailed tests were applied where directional hypotheses existed. Multiple comparison correction used Bonferroni when there were fewer than 15 comparisons and false-discovery rate (FDR) otherwise. Effect sizes for paired comparisons were reported as Cohen's d.

All 13 participants exceeded the conventional NDE threshold (≥7) for their DMT session; one participant also scored 7 following placebo. Repeated-measures ANOVA showed a strong main effect of condition on NDE scores [F(1,12) = 118.95, p = 1.39e-7], a main effect of NDE subscale [F(4,48) = 59.36, p = 5.39e-18] and a condition × subscale interaction [F(3,36) = 11.92, p = 1.4e-5]. The total NDE score was significantly higher after DMT than placebo (t = 10.91, df = 12, p = 1.39e-7) with a large effect size (Cohen's d = 3.09). Fifteen of the 16 individual NDE items had higher scores under DMT than placebo and ten items reached significance after FDR correction. Measures of ego-dissolution and mystical-type experience were also markedly increased by DMT. The EDI total score was significantly greater under DMT than placebo (t = 6.98, df = 12, p = 1.47e-5, Cohen's d = 2.67). MEQ analyses showed a main effect of condition [F(1,12) = 133.27, p = 7.43e-8], a subscale effect [F(3,36) = 4.66, p = 0.007] and a condition × factor interaction [F(3,36) = 3.35, p = 0.03]; the MEQ total score increased robustly under DMT (t = 10.11, df = 12, p = 3.17e-7, Cohen's d = 3.81). Correlations between DMT–placebo difference scores showed the NDE scale related to both EDI (r = 0.69, r2 = 0.47, p = 0.0096) and MEQ (r = 0.90, r2 = 0.81, p = 2.60e-5). Among MEQ factors, the Mystical and Transcendence of Time and Space factors showed particularly strong relationships with the NDE total. Baseline trait correlations indicated that higher PDI scores correlated with larger DMT-induced NDE scores (r = 0.61, r2 = 0.37, p = 0.013, one-tailed). Absorption (MODTAS) correlated with NDE scores (r = 0.57, r2 = 0.33, p = 0.02, one-tailed), but this did not survive correction for multiple comparisons (Bonferroni threshold reported as 0.0125), and exclusion of an outlier reduced the association to a non-significant trend (r = 0.45, p = 0.07, one-tailed). Age did not correlate significantly with NDE scores (r = -0.36, p = 0.16). When DMT-induced NDE scores were compared with a gender- and age-matched sample of people reporting actual NDEs, total NDE scores were comparable (t = 1.85, df = 12, p = 0.089, Cohen's d = 0.49), and subscale ratings did not differ meaningfully. Only one NDE item—"coming to a border or point of no return"—was rated higher by the actual NDE group (t = 2.74, df = 12, p = 0.018 uncorrected), but this difference did not survive multiple-comparison correction. Overall, the pattern of NDE features under DMT closely overlapped that reported by the matched actual NDE group.

Timmermann and colleagues interpret their findings as showing a striking phenomenological overlap between DMT-induced experiences and features commonly reported in NDEs. They highlight that all participants reached the conventional NDE threshold after DMT, most NDE items were elevated relative to placebo, and DMT-induced NDE scores were strongly associated with measures of mystical experience and ego-dissolution. The Mystical and Transcendence of Time and Space factors of the MEQ showed particularly strong relationships with NDE total scores, suggesting common experiential components such as unity, altered time–space perception, and profound positive affect. The authors note that baseline delusional ideation (PDI) correlated with stronger DMT-induced NDE scores and that absorption showed a trend-level relationship, implying that individual traits and pre-existing belief frameworks may shape endorsement of NDE-like phenomena. They discuss how cultural, contextual and personality variables have previously been linked to both psychedelic responses and actual NDE reports and suggest that such factors likely modulate the content and intensity of both states. Possible neurobiological commonalities are discussed cautiously. The authors reference prior models emphasising serotonergic and medial temporal lobe involvement in NDE phenomenology and suggest that reduced top-down cortical control over medial temporal structures under psychedelics might contribute to vivid imagery, entity encounters and autobiographical recollection seen in both states. They also propose that the unitive experience associated with ego-dissolution may be the core experiential element bridging mystical, psychedelic and near-death phenomena and that such experiences have been implicated in lasting therapeutic or psychological benefits. Limitations acknowledged by the study team include small sample size, non-uniform DMT dosing (dose-finding aspect), single-blind design with placebo always administered first (potential order or priming effects), and differing inclusion criteria between the DMT sample and the actual NDE comparison group (the latter required a threshold NDE score). The authors also consider the possibility that suggestibility during psychedelic states, the liberal threshold of the NDE scale, and contextual differences between laboratory and life-threatening settings could influence results. They recommend more detailed phenomenological capture (for instance, dynamic temporal sampling and structured interviews) and further neurobiological investigation to clarify overlaps and mechanisms.

The authors conclude that intravenous DMT can produce experiences that closely resemble many features of bona fide near-death experiences as measured by a standard NDE instrument, with a pattern of effects comparable to a matched sample of actual NDE experiencers and strong associations with mystical-type and ego-dissolution phenomena. They emphasise that individual differences—such as delusional ideation and, to a lesser extent, absorption—appear to modulate the intensity and quality of these NDE-like experiences. Timmermann and colleagues argue that these results warrant further research into the shared phenomenology and neurobiology of DMT-induced states and NDEs, while acknowledging contextual and methodological caveats; they suggest that better understanding these overlaps may have implications for how we conceptualise and study the psychology and neurobiology of dying and profoundly transformative experiences.